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New treatments for chronic obstructive pulmonary
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ABSTRACT
Chronic obstructive pulmonary disease is currently considered a systemic disease, presenting structural and metabolic
alterations that can lead to skeletal muscle dysfunction. This negatively affects the performance of respiratory and
peripheral muscles, functional capacity, health-related quality of life and even survival. The decision to prescribe ergogenic
aids for patients with chronic obstructive pulmonary disease is based on the fact that these drugs can avert or minimize
catabolism and stimulate protein synthesis, thereby reducing the loss of muscle mass and increasing exercise tolerance.
This review summarizes the available data regarding the use of anabolic steroids, creatine, L-carnitine, branched-chain
amino acids and growth hormones in patients with chronic obstructive pulmonary disease. The advantage of using these
ergogenic aids appears to lie in increasing lean muscle mass and inducing bioenergetic modifications. Within this
context, most of the data collected deals with anabolic steroids. However, to date, the clinical benefits in terms of
increased exercise tolerance and muscle strength, as well as in terms of the effect on morbidity and mortality, have not
been consistently demonstrated. Dietary supplementation with substances of ergogenic potential might prove to be a
valid adjuvant therapy for treating patients with advanced chronic obstructive pulmonary disease, especially those
presenting loss of muscle mass or peripheral muscle weakness.
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INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD)
is characterized by airflow limitation that is not fully
reversible. It is typical ly progressive and
accompanied by an abnormal inflammatory response
of the lungs to noxious gases or particles.(1) Although
the drug therapy is specifically designed for the
primarily affected organ, the lung, the impact of
the bronchodilator and anti-inflammatory therapy
on exercise capacity can be modest.(2)
This fact can be explained by new evidence that
indicates that skeletal muscle dysfunction syndrome,
characterized by atrophy (sarcopenia) and loss of
muscle strength, is an important factor for the
decreased exercise tolerance seen in patients with
COPD.(3)  The etiology of this syndrome seems to be
multifactorial, involving deconditioning, systemic
hypoxia or hypercapnia, as well as alterations
induced by age, drugs and nutritional depletion.
Progressive weight loss is a common finding in
this disease and can be identified in up to 50% of
patients, especially in those with predominant
pulmonary emphysema.(4) Such weight loss is a
negative prognostic factor, regardless of the degree
of airway obstruction,(5) and has been correlated with
increased morbidity and mortality(6) (Figure 1). An
energy imbalance, caused by reduced consumption
and increased basal energy metabolism, seems to
be associated with weight loss.(7) Weight loss is
commonly accompanied by a reduction in skeletal
muscle mass, (8) probably due to systemic
inflammation, which is characterized by high levels
of TNF-(9) and IL-6 (potentially involved in the
anorexia seen in these patients) ,  hypoxia
(contributing to low peripheral oxygen saturation
with consequent negative effects on the structure
and function of the skeletal muscle), dyspnea (which
results in lower food intake) and physical inactivity.
Finally, it is notable that malnutrition itself(10) results
in protein metabolization as a way of obtaining
substrate (Figure 2).(11)
In healthy individuals, ergogenic supplementation
is used to increase exercise tolerance, postpone
fatigue or stimulate muscle protein synthesis, thus
improving physical performance.(12) In patients with
COPD, the use of hormone and protein
supplementation is intended to bring ergogenic
benefits, especially those related to increased
synthesis or decreased protein metabolism.(13)
The objective of this review was to summarize
the current knowledge about the supplementation
of ergogenic substances in patients with COPD,
providing the theoretical bases for its rational use
in the clinical context. We included articles and
abstracts published between 1980 and 2005,
written in English or Portuguese, indexed in the
LILACS, Pubmed or Medline databases and related
to the supplementation of ergogenic substances for
patients with COPD. It should be specifically noted
that the present review does not cover energy/caloric
supplementation or the optimization of nutritional
support for patients with COPD.
ANABOLIC STEROIDS
Anabolic steroids are synthetic hormones similar
to testosterone, which is the most important
Figure 1 - Survival curve based on FEV1 and transversal cross-sectional area of the thigh (TCAT)(5)
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hormone secreted by the interstitial cells of the
testis. They affect the development of the male
sexual characteristics, promoting muscle hypertrophy
and reduction of body fat.(14)
In humans, the prolonged use of high doses of
anabolic steroids can result in the deterioration of
the normal endocrinal function of the testosterone
and increased concentration of estradiol, a female
hormone that promotes the development of female
characteristics. Other side effects, such as higher
cholesterol (with lower levels of high density
lipoprotein), liver injury, prostatic hyperplasia,
impotence and sterility, can occur.(12) The significant
anabolic effect of steroids has stimulated various
researchers to investigate the potential therapeutic
effects of these substances (Chart 1).
Intramuscular administration of nandrolone
decanoate (Deca-Durabolin®) was used in a study
that involved patients with moderate to severe
COPD, with and without muscle depletion.(14)
Different doses were used for males (50 mg) and
females (25 mg) for 8 weeks. An interesting
observation made by the authors was that the
depleted patients who received hypercaloric
supplementation (420 kcal) in addition to
nandrolone presented greater weight gain, lean body
mass and respiratory muscle strength than did the
individuals who received only nutrit ional
supplementation.
In a randomized, controlled clinical trial
conducted in Brazil, stanozolol supplementation (12
mg per day delivered orally for 27 weeks) and
intramuscular administration of testosterone (a single
250 mg dose given at baseline) was evaluated in
patients with low body weight (body mass index
lower than 20 kg/m2) and reduced maximal
inspiratory pressure (< 60% of predicted).(15)
Concomitant training of inspiratory muscles and
lower l imbs was administered using a
cycloergometer. Those authors observed significant
increases in body mass index, lean body mass, and
muscle circumference of arm and thigh in the
supplemented group in relation to the control group
(placebo combined with training). However, no
changes were observed in the 6-minute walk test
results or in maximum exercise capacity.
In another study, oxandrolone supplementation
(10 mg, orally, for four months) was given to
patients with moderate to severe COPD presenting
mean forced expiratory volume in 1 second (FEV1 )
of 34 ± 15.8% of predicted and with low body
weight (90% of the ideal).(16) The authors observed
increased body weight, mainly in terms of lean body
mass, clinically significant increases in the distance
covered on the 6-minute walk test (> 65 meters for
most patients) and progressive decreases in the use
of medication. The most common side effect was
edema (seen in 17%), which was treated by reducing
Figure 2 - Possible mechanisms negatively influencing insulin-like growth factor 1(IGF-1) and their skeletal muscle
consequences
Hypoxia Malnutrition Energy expenditure
     Systemic InflammationOxidative stress
 IGF-1 Corticosteroids
Generalized atrophy
  Protein synthesis
Protein degradation
Muscle mass
Exercise capacity
J Bras Pneumol. 2005;32(1):66-74
 69New treatments for chronic obstructive pulmonary disease using ergogenic aids
the dosage or by discontinuing the medication and
administering diuretics.
In another study, 50 mg of intramuscular
nandrolone decanoate was administered every 2
weeks for 8 weeks in a group of men with moderate
to severe COPD (FEV1 = 38 ± 17% of predicted),
accompanied by pulmonary rehabilitation.(17) In
relation to a control group, the supplemented
patients presented greater muscle mass gain.
However, the improvements in muscle function,
exercise capacity and state of health were similar in
both groups.
In a placebo-controlled study, 100 mg of
testosterone was administered to men with
moderate to severe COPD (FEV1 = 60% of predicted)
who presented low testosterone levels (400  g/dl).(18)
The authors observed greater increases in lean body
mass and muscle strength in the group that received
supplementation and training in relation to a group
that received testosterone only. The magnitude of
the lean body mass increase observed in this study
was superior to those described in previous
studies,(14-16) probably because the dose of anabolic
steroid was six times higher.
In a recent study, 250 mg of testosterone were
administered to men with moderate to severe COPD
(FEV1 < 60% of predicted) every 4 weeks for 26
weeks, without rehabilitation intervention. There was
an increase in lean body mass, a decrease in fat
mass and improvement in the quality of the sex life
in the supplemented group in relation to the placebo
group.(19)
The correlation between reduction of muscle mass
and mortality in patients with COPD(6) could justify
the use of steroids in this population, since
supplementation with these substances has been
found to be efficient in increasing body weight and
muscle mass.(14-19) However, before initiating this
therapy, we have to ensure that there is no prostatic
neoplasm or significant liver disease since both
processes can be accelerated by the supplementation.
In addition, it should be borne in mind that most
Chart 1 - Main characteristics of studies that used anabolic steroids in patients with COPD
COPD: chronic obstructive pulmonary disease; BMI: body mass index; MIP: maximal inspiratory pressure; 6MWT: 6-
minute walk test; =: without alterations;  : increase;    decrease; W: workload; VO2: oxygen consumption
 Author,        N at patients    Inclusion criteria Supplementation              Results
 year         Controls
 Schols et al,    110/107        moderate to Nandrolone Decanoate Weight and MIP:  ↑
 1995                severe COPD    50mg: (depleted)
   25 mg) for 8 weeks  Lean body Mass: ↑
(depleted or undepleted)
 6MWT:  =
 Ferreira et al,    10/7        EMI < 20 Testosterone 250 mg in the    BMI: ↑
 1998     kg/m2 MIP basal period and stanozolol   Lean body mass: ↑
               < 60% predicted 12 mg for 27 weeks    6MWT: =
 Yeh et al,         55/0     moderadate to Oxandrolone 10 mg for 4    Weight:  ↑
 2002                severe COPD months    Lean body mass: ↑
    Weight < 90% ideal    6MWT: ↑
 Creutzberg et al, 33/30        moderate to Nandrolone Decanoate:    Lean body mass: ↑
 2003     severe COPD 50 mg for 8 weeks    MIP: ↑
 Casaburi et al,   23/24        moderate to Testosterone 100 mg/week    Lean body mass:  ↑
 2004     severe COPD for 10 weeks    Peripheral muscle
    testosterone < 400 n/dl    strength: ↑ VO2 and W
   peak:↑
 Svartberg et al,   29/0     Men moderate to Testosterone 250 mg    Lean body mass: ↑
 2004     severe COPD every 4 weeks for 26 weeks    Improvement in
   quality of sex life
+
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studies in which the use of anabolic steroids was
combined with physical training used endurance
exercises,(14-15,17,19) and only one study involved
strength training.(18) Therefore, there are insufficient
data in the literature to recommend a specific type
of physical training to be combined with
supplementation, although it is reasonable to
suppose that the use of strength training is more
appropriate since it would tend to magnify the
possible hypertrophic effects on muscle. It is also
important to observe that it is often necessary to
previously adjust eating habits or energy
supplementation in order to optimize the treatment.
More randomized and placebo-controlled clinical
trials are still needed in order to evaluate the long-
term effects of the use of anabolic steroids combined
with physical training.
CREATINE
 Creatine is a nutrient found in foods such as
fish and meat and can be endogenously synthesized
from other amino acids (glycine, arginine and
methionine) found in the liver, kidneys and
pancreas.(20-21) The majority of the creatine found in
the body resides in the skeletal muscle in the form
of phosphocreatine. Phosphocreatine is the first
energy reserve depleted during activities of high
energy demand that vary from ten seconds to
approximately one minute.(22) However, its stores are
resynthesized within a few minutes, which makes it
important in intermittent exercises.(20)
Creatine supplementation has been often used
by athletes. However, recent evidence indicates that
creatine can be useful in the treatment of diseases,
mainly those that result in atrophy and muscle
fatigue.(22) Another relevant aspect that would justify
the use of creatine in patients with COPD is that
this population presents redistribution of types of
muscle fibers, with predominance of type II fibers,(23)
which are characterized by rapid contractions and
present greater anaerobic capacity than do type I
fibers. Studies reveal that type II fibers use more
phosphocreatine during exercise.(20) Therefore,
creatine supplementation, together with physical
training, can be a valid alternative means of
increasing exercise tolerance.
In a randomized, double-blind, placebo-controlled
study, the effect of creatine supplementation was
evaluated in 26 patients with moderate to severe
COPD.(24) The patients were submitted to endurance
and strength training of the lower limbs for 12 weeks.
The authors found no statistically significant differences
between the groups regarding exercise capacity and
muscle strength. However, this study was only
published in form of abstract.
In a recent randomized, double-blind, placebo-
control led study, the effect of creatine
supplementation was evaluated in 38 stable patients
with moderate to severe COPD (FEV1 = 46 ± 15% of
predicted).(25) Supplementation was divided into two
phases: loading phase (15 g/day for 2 weeks) and
maintenance (5 g/day for 8 weeks), the latter
Chart  2 - Main characteristics of studies that used human growth hormone in patients with COPD
 Author, year    N patients  Inclusion criteria            Supplementation            Results
                   Controls
 Suchner et al, 6/0 moderate to severe rhGH: 0.03 mg/kg/day for 4 BEE:↑ Oxidation of
 1989 COPD with weight loss days, followed by 0.06 fats: ↑ Oxidation of
mg/kg/day for 4 days protein and glucose: ↓
 Pape et al, 7/0 FEV1< 70% predicted rhGH 0.05 mg/kg/day Nitrogen Balance: ↑
 1991 FEV1/FVC < 0,65 for 3 weeks Body Weight: ↑
ideal weight < 90% MIP: ↑
 Burdet et al,       8/8 FEV1/FVC  < 70% rhGH 0.15 IU/kg Lean body mass: ↑
ideal weight < 90% for 3 weeks Peripheral Respiratory
Muscle Strength:  =
6MWT:  =
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity;
rhGH: recombinant human growth hormone; MIP: maximal inspiratory pressure; BEE: basal energy expenditure; 6MWT:
six-minute walk test; =: without alterations;   increase;   decrease
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combined with physical training. The authors
observed that the use of creatine resulted in
increases in lean body mass, strength and peripheral
muscle endurance, especially after the addition of
training. The results of this study suggests that
creatine supplementation may begin to be
considered part of the available ergogenic arsenal
for lean body mass increase and structural and
functional improvement of skeletal muscle in COPD.
It is of note that creatine is known to be safe, with
few side effects: water retention (in the intracellular
compartment), muscle pain and occasional cramps.
However, as in other ergogenic therapies, additional
follow-up studies are necessary to evaluate the actual
long-term benefits of creatine supplementation in
COPD.
L-CARNITINE
The metabolite L-carnitine is essential to the transfer
of long-chain fatty acids, and of cytosol to the
mitochondrial matrix, where ß-oxidation (the oxidation
of fatty acids) occurs, resulting in energy production.(26)
Various studies published in the sports medicine
literature have demonstrated the ergogenic effect
of L-carnitine in improving performance, showing
that it increases the oxidation of fatty acids,
decreases the rates of muscle glycogen depletion
and increases resistance to muscle fatigue. However,
the use of L-carnitine for long periods in untrained
healthy individuals has not been shown to improve
physical performance.(26)
In another study conducted in Brazil, L-carnitine
supplementation combined with physical training
was evaluated in patients with COPD (FEV1 < 65%
of predicted) for a period of 6 weeks at a dosage of
2 g/day.(27) The authors observed greater attenuation
of the heart rate in a supplemented group in relation
to an unsupplemented group. In addition, the
distance covered in the 6-minute walk test was
greater in the group that received supplementation
and physical training.
It seems logical to suppose that L-carnitine
supplementation should be used preferably in
individuals with satisfactory body composition,
especially in terms of adipose reserve, since it
stimulates the use of fat as substrate. As with the
other substances, further studies of L-carnitine are
needed in order to determine its potential benefits
in patients with COPD.
BRANCHED-CHAIN AMINO ACIDS
The branched-chain amino acids (BCAAs) leucine,
isoleucine and valine are primarily metabolized in
the skeletal muscle as energy substrate or are used
as precursors of the synthesis of other amino acids
and proteins.(28) These BCAAs exert a significant
influence on the metabolism of glutamine and
together serve as an important energy substrate for
the brain, kidneys, liver and heart. The increased BCAA
concentration in the skeletal muscle reduces
glutamate dehydrogenase activity, thereby limiting
glutamine degradation.(28) Intracellular glutamate
plays a central role in the preservation of high-energy
phosphates in muscle,(29) and its low intramuscular
levels have been correlated with early lactic acidosis
during exercise.(30) Infusion with BCAAs stimulates
synthesis and decreases protein degradation, thereby
regulating muscle renovation.(31) During prolonged
exercises, BCAAs can constitute an oxidative substrate
for the skeletal muscles. Under conditions of relative
energy shortfalls, such as those induced by sepsis,
trauma and hypoxia, the BCAA metabolism is
accelerated in the skeletal muscle.(28)
In studies evaluating the profile of amino acids
in the plasma and skeletal muscle of patients with
COPD, decreased BCAA levels were observed in the
skeletal muscle of patients with predominance of
emphysema(32) and in the plasma of patients with
body weight at 90% of the ideal.(33) The rationale
behind the use of BCAAs in COPD is also based on
the observation that its oral administration in healthy
elderly individuals stimulates the transfer of amino
acids to the muscle, which has been correlated with
protein synthesis,(29) especially when ingested before
or immediately after exercise.
To date, there have only been two studies related
to the use of BCAAs in patients with COPD.(34-35) In
one of those studies, the effects of nutritional
supplementation with a BCAA (1.5 times the baseline
energy expenditure for a year) were examined in
undernourished patients with COPD.(34) The authors
reported improvement in the nutritional state, as
well as increased respiratory muscle function and
improved quality of life. However, because this study
was not published in English, it was not possible to
analyze the inclusion criteria, drop-out rates, quality
of life improvement, supervised versus unsupervised
ingestion of the BCAAs and methods of evaluating
respiratory muscle strength.
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The other was a nonrandomized study using a
BCAA at the dosage of 1 IU/7 kg for 5 weeks in a
group of patients with COPD.(35) There was
improvement in the peak oxygen consumption and
maximum load in the groups studied, although the
difference between the groups was not statistically
significant. The authors observed decreased
hypoxemia at rest and hypercapnia between the
beginning and the end of the study in the
supplemented group. However, there was no mention
of whether the patients were hospitalized or not.
Therefore, the improvement in their blood gas analysis
results could be due to the recovery of clinical stability
rather than, as was speculated by the authors, to the
direct effect of the BCAAs on the respiratory centers
or on the ventilation/perfusion ratio.
In the few studies that discuss the use of BCAAs
in patients with COPD, the quality of the methodology
was poor. However, there is a theoretical basis for
further investigation of these substances in order to
evaluate their possible benefits in these patients.
GROWTH HORMONE
The human growth hormone (hGH) is a
polypeptide composed of 191 amino acids released
by the hypophysis resulting from certain specific
physiological stimuli. Through techniques of genetic
engineering, it is possible to obtain its synthetic
form, recombinant hGH (rhGH). This substance can
accelerate the oxidation of fatty acids and increase
the capture of amino acids, in addition to exerting
a diabetogenic effect secondary to the decreased
transfer of glucose through the cellular membrane.
Other rhGH-related side effects include peripheral
edema, hypothyroidism and gynecomastia.(36)
The hGH stimulates the liver to produce insulin-
like growth factor 1, a molecule that binds to plasma
proteins. This growth factor is the most important
anabolic mediator of hGH(37) and plays a central role
in regulating metabolism, as well as in cell
proliferation and differentiation(38) (Figure 2).
Therefore, the use of hGH has potentially benefits
in COPD (Chart 2).
Some authors have evaluated the effect of
rhGH in patients with advanced COPD (FEV1 =
29 ± 6% of predicted)  v ia subcutaneous
administration (30 mg/kg/day for four days, and
later on 60 mg/kg/day for four more days), in 6
patients with weight loss who were receiving
parenteral nutrition.(39) The administration of the
rhGH was accompanied by increased baseline
energy expenditure and oxidation of fats, in
addition to decreased glucose oxidation. An
improvement in nitrogen balance, which is a
potentially relevant effect for patients with low
body weight, was observed.
Other authors(40) analyzed the effects of rhGH
supplementation (0.05 mg/kg/day of subcutaneous
administration for 3 weeks) in 7 patients with COPD
(FEV1 < 70% of predicted) and low body weight (<
90% of ideal weight).(41) There was significant weight
gain and improved nitrogen balance. In functional
terms, respiratory muscle strength, evaluated by
maximal inspiratory pressure, increased by an
average of 33% in 6 patients and decreased by 8%
in 1. There were no changes in respiratory muscle
endurance.
In another study,(42) the effects of rhGH
administration (0.15 IU/kg/day of subcutaneous
administration for 3 weeks) was evaluated in 16
stable patients (FEV1 < 70% of predicted and body
weight < 90% of ideal).(41) The authors observed an
increase in muscle mass, although without any
accompanying increase in respiratory muscle
performance or exercise capacity. Secondarily, there
was increase in the baseline energy expenditure and
an elevation of the metabolic rate (oxygen
consumption and production of carbon dioxide)
attributed to the thermogenic effect of rhGH, in
addition to the increase in protein renovation and
lipolysis.
The effects of rhGH on the functional capacity
of patients with COPD are controversial and should
be carefully analyzed due to the reduced number
of publications, lack of control groups and isolated
(without physical training) use of ergogenic
therapy.(39-40) In addition, the studies were carried
out for a short period of time (approximately 3
weeks), showing acute alterations in metabolism
and muscle strength. Therefore, the long-term
effects of rhGH administration remain unknown.
Another aspect to be explored in future studies is
the cost-effect iveness rat io ,  s ince rhGH
supplementation is expensive and, as previously
stated, its clinical benefits have yet to be
demonstrated. These aspects, together with the
limitation of subcutaneous administration, can
explain why no studies of rhGH use in COPD have
been published in the last eight years.
J Bras Pneumol. 2005;32(1):66-74
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CONSENSUAL RECOMMENDATIONS
Considering the impact that the reduced muscle
mass seems to exert on morbidity and mortality in
patients with COPD, relatively few controlled
randomized studies of ergogenic interventions have
been carried out. A review of the literature available
allows us to suggest that, among the ergogenic
supplements evaluated, anabolic steroids, used in
appropriate doses and for a limited period of time,
hold the most promise as a treatment for COPD.
Preliminary evidence also shows good results with
the use of creatine and L-carnitine and, to a lesser
degree, with BCAAs. The use of rhGH in Brazil seems
to be limited by the high cost and by the fact that
it requires parenteral administration.
Ergogenic supplementation can be added to the
conventional treatment of advanced COPD in the
following situations: patients with muscle depletion
(lean body mass index = 16 kg/m2 for men and = 15
kg/m2 for women)(43) or with body weight lower than
90% of ideal weight, according to the Metropolitan
Life Insurance standards(41); patients with weight loss
greater than 10% of their usual weight over a six-
month period or greater than 5% of their weight in
the preceding month(29); patients in which eating is
found to be insufficient, according to information
obtained through questionnaires,(44) in relation to the
baseline energy expenditure calculated through
predictive equations(45) or through indirect
calorimetry.(46) Finally, due to the modulatory effect
of the use of corticosteroids in response to treatment
with nutritional supplementation, the use of ergogenic
supplements can be useful in patients who make use
of these drugs regularly.
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